Get started
Author

Sarah J. White

Randomized controlled trial comparing impact on platelet reactivity of twice‐daily with once‐daily aspirin in people with Type 2 diabetes
2015 · M. A. Bethel, P. Harrison, et al. · Diabetic Medicine · 61
PDF
Safety of antipsychotics in people with intellectual disability
2011 · Valeria Frighi, Matthew T. Stephenson, et al. · The British Journal of Psychiatry · 58
PDF
11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial
2023 · Nantia Othonos, Riccardo Pofi, et al. · Nature Communications · 48
PDF
Vitamin D deficiency in patients with intellectual disabilities: prevalence, risk factors and management strategies
2014 · Valeria Frighi, Alireza Morovat, et al. · The British Journal of Psychiatry · 45
PDF
Vitamin D , bone mineral density and risk of fracture in people with intellectual disabilities
2018 · V. Frighi, A. Morovat, et al. · Journal of Intellectual Disability Research · 24
Sodium‐glucose cotransporter 2 inhibition does not reduce hepatic steatosis in overweight, insulin‐resistant patients without type 2 diabetes
2019 · Thomas Marjot, Charlotte J Green, et al. · JGH Open · 22
PDF
Evaluation of a Self-Administered Oral Glucose Tolerance Test
2013 · M. Angelyn Bethel, Hermione C. Price, et al. · Diabetes Care · 22
Co-administration of 5α-reductase Inhibitors Worsens the Adverse Metabolic Effects of Prescribed Glucocorticoids
2020 · Nantia Othonos, Thomas Marjot, et al. · The Journal of Clinical Endocrinology & Metabolism · 14
PDF
Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post‐meal glucose excursions and glucagon in type 1 diabetes patients
2020 · Chitrabhanu Ballav, Archana Dhere, et al. · Endocrinology Diabetes & Metabolism · 10
Dose-dependent and tissue-specific adverse effects of exogenous glucocorticoids: insights for optimizing clinical practice
2025 · Riccardo Pofi, Nantia Othonos, et al. · Journal of Endocrinological Investigation · 9
PDF
A non‐invasive frequent home blood glucose monitor
2002 · H Lenzen, BA Barrow, et al. · Practical Diabetes · 7
Identification of a human blood biomarker of pharmacological 11β‐hydroxysteroid dehydrogenase 1 inhibition
2023 · Cristina Gómez, Zerin Alimajstorovic, et al. · British Journal of Pharmacology · 3
PS-107-SGLT2 inhibition does not reduce hepatic steatosis in overweight, insulin resistant patients without type 2 diabetes
2019 · Thomas Marjot, Charlotte Green, et al. · Journal of Hepatology · 1
Depot-specific molecular remodelling of human adipose tissue and liver following bariatric surgery revealed by longitudinal multi-omic profiling
2026 · Niall J. Dempster, Frederik Steensgaard Gade, et al. · Metabolism
PDF
Carbonyl reductase 1 regulates prednisolone clearance and modifies its adverse effect profile
2026 · Riccardo Pofi, Tom Potter, et al. · European Journal of Endocrinology
PDF
O40 MASLD is a night-time disease driven by nocturnal hepatic, adipose, and skeletal muscle insulin resistance
2024 · Thomas Marjot, Sarah White, et al. · Gut
Identification of a human blood biomarker of pharmacological 11β-hydroxysteroid dehydrogenase 1 inhibition
2023 · Gómez, Cristina, Alimajstorovic, Zerin, et al. · Zenodo (CERN European Organization for Nuclear Research)
NAFLD is a night-time disease driven by nocturnal hepatic, adipose, and skeletal muscle insulin resistance
2023 · Thomas Marjot, Sarah White, et al. · Journal of Hepatology
GW24-e3986 Aspirin given twice daily reduced the platelet reactivity more than once daily in people with type 2 diabetes without cardiovascular disease
2013 · Sun YiHong, M Angelyn Bethel, et al. · Heart
Works count: 19
Citation count: 324
H-index: 9
I10-index: 9
Year
Topic
Type